Tier 3 — preclinical

Anti-oxidant treatment in obstructive sleep apnoea syndrome

K Sadasivam, K Patial, V K Vijayan, K Ravi
Indian J Chest Dis Allied Sci 2011 53(3):153-162

Bibliography

PubMed
PMID 21838198
DOI
10.5005/ijcdas-53-3-153
Funding
Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
Competing interests
Competing-interest disclosure was not located in the indexed record reviewed; consult the source publication for the full declaration.

Study snapshot

DesignRandomized placebo-controlled polysomnography study
ModelHuman
Sample20 adults with obstructive sleep apnea; 10 NAC and 10 placebo
InterventionOral NAC 600 mg three times daily versus placebo
Duration30 days
EndpointsSleep efficiency; Slow-wave sleep; Apnea-hypopnea index; Arousals; Oxygen desaturation; Epworth sleepiness; Snoring

What the study showed, in plain terms

Small 30-day randomized study of 1,800 mg/day NAC in obstructive sleep apnea.

Key findings

Within the NAC group, several polysomnographic measures and daytime sleepiness improved over 30 days; the study was too small to establish NAC as an alternative to CPAP.

What this study can and cannot tell us

Only 20 participants, short duration, old single-center study and limited between-group reporting; not evidence for insomnia or general sleep enhancement.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology